NanoViricides Receives Analyst Coverage Initiation with Outperform Rating and $6 Price Target

NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.

Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola.

NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

The lead drug candidate is NV-387, a broad-spectrum antiviral drug planned for the treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. Another advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.

The company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. NanoViricides’ platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel.

For more information, visit the company’s newsroom at https://ibn.fm/NNVC.